FMCG major Marico has announced that it will be investing in Revolutionary Fitness, owner of health and fitness app Revofit. The company stated that it will acquire around 22.5 percent stake in the health startup.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
AstraZeneca has collaborated with Emulate integrate an organ-on-a-chip technology into the R&D program of the pharma giant. It is meant to expedite the technology’s development within the company.
This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
The implementation of privacy protocols and security controls is pertinent to protecting patient records and sensitive data. However, the threat to patient safety, the core of every modern health system, being compromised is growing rapidly owing to network-connected medical devices.
A simple key strategy discovered by the research team at the London School of Tropical Medicine, will turn out to be a major breakthrough in the field of Malarial prevention. Malaria-infected children were more prone to malarial mosquitoes by producing distinctive skin smells, compared to uninfected children.
As a new, erratic administration consolidated its position in the White House and firmed its foundations in the federal government, 2017 turned out to be uncertain for the biopharma industry. Then President-elect Donald Trump saying that the industry was getting away with murder on pricing did not bode well for the industry but more than a year later after the President assuming office, real reform has been spared for biopharma.
A particular proposal regarding displaying drug prices in TV ads flummoxed pharma marketers and ad agencies following the unveiling of the drug-pricing agenda by President Trump. Marketers have been hounded with the whys and hows of the proposal even as the administration remains firm on its implementation.
On April 20, 2018, Qiagen announced the FDA approval of the novel test named PartoSureTM, used for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
Scientists from the Department of Chemistry at Imperial have developed a small, user-friendly, accurate and cost-effective sensor to test arsenic levels in drinking water within a minute. When a drop of water hits the test strip, it gives the arsenic level count digitally.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.